Lineage director granted 125,000 stock options

Lineage Cell Therapeutics director Michael H. Mulroy received a grant of stock options representing 125,000 common shares.

Rhea-AI Filing Summary

Lineage Cell Therapeutics director Michael H. Mulroy received a grant of stock options representing 125,000 common shares. The options carry an exercise price of $1.30 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market purchase or sale.

The options will vest and become exercisable on the earlier of July 1, 2027 or the date of the company’s next annual shareholder meeting, subject to his continuous service with the company.

Insider Trade Summary

Grant/Award: 125,000 shares

Grant/Award 1 txn

Insider Mulroy Michael H.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	125,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 125,000 contracts (Direct)

Footnotes (1)

1. F1. Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.

Key Figures

Option grant size: 125,000 options Exercise price: $1.30 per share Expiration date: July 1, 2036 +2 more

5 metrics

Option grant size 125,000 options Stock Option (Right to Buy) awarded to director

Exercise price $1.30 per share Option exercise price for underlying common shares

Expiration date July 1, 2036 Option term ending

Underlying shares 125,000 shares Common shares underlying the option grant

Vesting trigger date July 1, 2027 Latest vesting date, or earlier at next annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, grant, award, or other acquisition, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.3000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-07-01T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vest and become exercisable financial

"Will vest and become exercisable on the earlier of July 1, 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Michael H. Mulroy acquire in the latest LCTX Form 4 filing?

Michael H. Mulroy received a grant of stock options for 125,000 Lineage Cell Therapeutics common shares. The options are a compensation-related award, not an open-market trade, and give him the right to buy shares at a fixed exercise price.

What is the exercise price of Michael H. Mulroy’s new LCTX stock options?

The newly granted stock options have an exercise price of $1.30 per Lineage Cell Therapeutics share. This price is the cost per share he must pay to exercise the options and acquire the underlying common stock in the future.

When do Michael H. Mulroy’s LCTX stock options vest?

The options will vest and become exercisable on the earlier of July 1, 2027 or the date of Lineage Cell Therapeutics’ next annual shareholder meeting. Vesting is conditioned on his continuous service with the company through that time.

How many LCTX shares underlie Michael H. Mulroy’s stock option grant?

The stock option grant covers 125,000 underlying Lineage Cell Therapeutics common shares. Once vested and exercised at the $1.30 exercise price, each option would convert into one share of common stock, increasing his direct equity exposure.

Is the recent LCTX Form 4 a buy or sell transaction?

The Form 4 reflects an acquisition of derivative securities through a stock option grant, coded as a grant or award. It does not report any open-market buying or selling of Lineage Cell Therapeutics common shares by Michael H. Mulroy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mulroy Michael H.

(Last) (First) (Middle)

C/O LINEAGE CELL THERAPEUTICS

2173 SALK AVENUE, SUITE 200

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lineage Cell Therapeutics, Inc. [ LCTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.3	07/01/2026		A		125,000		(1)	07/01/2036	Common Shares	125,000	$0.00	125,000	D

Explanation of Responses:

1. Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.

	/s/ Alexandra Hernandez, as Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)